PEPTIDEREPORT

Video claim watch

Retatrutide Masterclass: How To Use It Optimally (Dose, Frequency, Diet, Exercise, & Supplements)

Long-form doctor-led retatrutide discussion with monitoring, diet, exercise, and supplement chapters that may shape reader search behavior.

Quinn Stillson MD channel1:14:50 runtime13K views when checked

Published Jun 26, 2026. Metadata checked Jun 30, 2026.

Watch on YouTube

Transcript review

6 material claims logged

Published with source gaps audit stateauto-captioned transcript6 operational-guidance flags1 source gap

Reviewed Jul 12, 2026. Next review Aug 12, 2026.

highest-risk item in the library because it provides operational guidance for an investigational drug. Use only as a claim-audit target.

auto-caption available; 18 creator chapters.

Claim-by-claim audit

What the video says, and what needs checking

00:06:55
Operational guidanceHigh-risk safety claim

Proposes laboratory-monitoring panels/frequency and interpretation.

Review topic: retatrutide / monitoring.

Checked against: Primary-source record still needed

phase-3 protocol and future label only; do not publish as a protocol.

Handling: This segment contains operational guidance for an unapproved product. Peptide Report does not reproduce or endorse those instructions.

00:15:32
High-risk evidence claimHigh-risk safety claimOperational guidance

Defines a lean-mass-loss threshold and later prescribes exercise, diet, protein timing, hydration, and supplement practices as retatrutide-specific optimization.

Review topic: body composition / supportive care.

Checked against: Impact of semaglutide on body composition in STEP 1

retatrutide-specific evidence is limited.

Handling: This segment contains operational guidance for an unapproved product. Peptide Report does not reproduce or endorse those instructions.

00:39:24
High-risk safety claimOperational guidanceHigh-risk commercial claim

Gives side-effect mitigation and supplement recommendations.

Review topic: adverse effects / supplements.

Checked against: Retatrutide phase 2 results: 24.2% weight loss (NEJM), Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial.

no recommendation should be carried over.

Handling: This segment contains operational guidance for an unapproved product. Peptide Report does not reproduce or endorse those instructions.

00:46:12
Operational guidanceHigh-risk regulatory claimHigh-risk safety claim

Discusses oral administration and then specific starting, escalation, maximum, split-frequency, time-of-day, and cycling schedules.

Review topic: retatrutide administration.

Checked against: Retatrutide phase 2 results: 24.2% weight loss (NEJM)

trial protocols only. Peptide Report should describe trial regimens historically, never convert them into instructions.

Handling: This segment contains operational guidance for an unapproved product. Peptide Report does not reproduce or endorse those instructions.

01:07:19
Operational guidanceHigh-risk evidence claim

Discusses staying on, cycling, and switching among GLP-1 drugs.

Review topic: chronic use / switching.

Checked against: Weight regain and cardiometabolic effects after withdrawal of semaglutide, Continued treatment with tirzepatide for maintenance of weight reduction

retatrutide withdrawal data are not established.

Handling: This segment contains operational guidance for an unapproved product. Peptide Report does not reproduce or endorse those instructions.

Connected research

Compounds discussed

Retatrutide Retatrutide has produced large weight reductions in randomized Phase 2 and Phase 3 trials, but it remains unapproved. Long-term outcomes, direct comparisons, rare risks, durability, and final regulatory decisions remain unresolved.

Source check

Records used in this claim audit

TRIUMPH-1: retatrutide in participants with obesity or overweight

ClinicalTrials.gov · Primary regulatory · Jul 3, 2023 · accessed Jul 12, 2026

Completed Phase 3 master protocol NCT05929066. The registry identifies TRIUMPH-1 as a randomized, double-blind, placebo-controlled study in adults without type 2 diabetes who have obesity or overweight.

12 linked pagesOpen original · clinicaltrials-retatrutide-triumph1

Retatrutide for Obesity: A Phase 2 Trial

New England Journal of Medicine · Peer reviewed · Jun 26, 2023 · accessed Jul 1, 2026

Retatrutide phase 2 obesity trial (NEJM 2023): at 12 mg, mean body weight fell 17.5% at week 24 and 24.2% at week 48; GI adverse events were most common.

12 linked pagesOpen original · nejm-retatrutide-phase2-2023